[DOI] [PubMed] [Google Scholar] 350.Nicholls D.P., Shepherd A.M.M
In the New England Journal of Medicine, Garvey and colleagues [5] report the results of the REDEFINE 1 trial, a 68-week, phase 3a double-blind, placebo-controlled and active-controlled trial evaluating the efficacy and safety of coadministered cagrilintide and semaglutide in adults with obesity [body mass index (BMI) 30 kg/m 2 ] or overweight (BMI 27 kg/m 2 ) with at least one weight-related comorbidity
Children and teenagers: Not recommended without medical supervision
Dosing Parameters in Clinical Settings Dose Range and Route Selection Preclinical dose-response studies demonstrate BPC-157 efficacy across an exceptionally wide dose range, from 10 nanograms per kilogram to 10 milligrams per kilogram, spanning six orders of magnitude
Biomed Chromatogr 38, e5946 (2024)
A phosphate buffer effectively solubilized interfering biomolecules in all experimental samples